Literature DB >> 8702993

Structure-function relationship of lipoprotein lipase-mediated enhancement of very low density lipoprotein binding and catabolism by the low density lipoprotein receptor. Functional importance of a properly folded surface loop covering the catalytic center.

S Salinelli1, J Y Lo, M P Mims, E Zsigmond, L C Smith, L Chan.   

Abstract

We examined the structure-function relationship of human lipoprotein lipase (hLPL) in its ability to enhance the binding and catabolism of very low density lipoproteins (VLDL) in COS cells. Untransfected COS cells did not bind to or catabolize normal VLDL. Expression of wild-type hLPL by transient transfection enhanced binding, uptake, and degradation of the VLDL (a property of LPL that we call bridge function). Heparin pretreatment and a monoclonal antibody ID7 that blocks LDL receptor-binding domain of apoE both inhibited binding, and apoE2/E2 VLDL from a Type III hyperlipidemic subject did not bind. However, LDL did not reduce 125I-VLDL binding to the hLPL-expressing cells, whereas rabbit beta-VLDL was an effective competitor. By contrast, LDL reduced uptake and degradation of 125I-VLDL to the same extent as excess unlabeled VLDL or beta-VLDL. These data suggest that binding occurs by direct interaction of VLDL with LPL but the subsequent catabolism of the VLDL is mediated by the LDL receptor. Mutant hLPLs that were catalytically inactive, S132A, S132D, as well as the partially active mutant, S251T, and S172G, gave normal enhancement of VLDL binding and catabolism, whereas the partially active mutant S172D had markedly impaired capacity for the process; thus, there is no correlation between bridge function and lipolytic activity. A naturally occurring genetic variant hLPL, S447-->Ter, has normal bridge function. The catalytic center of LPL is covered by a 21-amino acid loop that must be repositioned before a lipid substrate can gain access to the active site for catalysis. We studied three hLPL loop mutants (LPL-cH, an enzymatically active mutant with the loop replaced by a hepatic lipase loop; LPL-cP, an enzymatically inactive mutant with the loop replaced by a pancreatic lipase loop; and C216S/C239S, an enzymatically inactive mutant with the pair of Cys residues delimiting the loop substituted by Ser residues) and a control double Cys mutant, C418S/C438S. Two of the loop mutants (LPL-cH and LPL-cP) and the control double Cys mutant C418S/C438S gave normal enhancement of VLDL binding and catabolism, whereas the third loop mutant, C216S/C239S, was completely inactive. We conclude that although catalytic activity and the actual primary sequence of the loop of LPL are relatively unimportant (wild-type LPL loop and pancreatic lipase loops have little sequence similarity), the intact folding of the loop, flanked by disulfide bonds, must be maintained for LPL to express its bridge function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702993     DOI: 10.1074/jbc.271.36.21906

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Fatty acids increase glucose uptake and metabolism in C2C12 myoblasts stably transfected with human lipoprotein lipase.

Authors:  Warren H Capell; Isabel R Schlaepfer; Pamela Wolfe; Peter A Watson; Daniel H Bessesen; Michael J Pagliassotti; Robert H Eckel
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-07-13       Impact factor: 4.310

2.  Very-low-density lipoprotein binding to the apolipoprotein E receptor 2 is enhanced by lipoprotein lipase, and does not require apolipoprotein E.

Authors:  P J Tacken; F D Beer; L C Vark; L M Havekes; M H Hofker
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

3.  Not the mature 56 kDa lipoprotein lipase protein but a 37 kDa protein co-purifying with the lipase mediates the binding of low density lipoproteins to J774 macrophages.

Authors:  W L Hendriks; L C Van Vark; K Schoonderwoerd; H Jansen; L M Havekes
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

4.  The lipoprotein lipase (LPL) S447X gain of function variant involves increased mRNA translation.

Authors:  Gouri Ranganathan; Resat Unal; Irina D Pokrovskaya; Preeti Tripathi; Jerome I Rotter; Mark O Goodarzi; Philip A Kern
Journal:  Atherosclerosis       Date:  2011-12-27       Impact factor: 5.162

5.  Coexpression of novel furin-resistant LPL variants with lipase maturation factor 1 enhances LPL secretion and activity.

Authors:  Ming Jing Wu; Anna Wolska; Benjamin S Roberts; Ellis M Pearson; Aspen R Gutgsell; Alan T Remaley; Saskia B Neher
Journal:  J Lipid Res       Date:  2018-10-14       Impact factor: 5.922

Review 6.  Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL.

Authors:  Vassilis I Zannis; Angeliki Chroni; Monty Krieger
Journal:  J Mol Med (Berl)       Date:  2006-02-25       Impact factor: 4.599

7.  Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4.

Authors:  Alexander M Vezeridis; Konstantinos Drosatos; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2010-09-22       Impact factor: 5.922

8.  apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Alexander Vezeridis; Ioannis Dafnis; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

9.  Equivalent binding of wild-type lipoprotein lipase (LPL) and S447X-LPL to GPIHBP1, the endothelial cell LPL transporter.

Authors:  Kirsten Turlo; Calvin S Leung; Jane J Seo; Chris N Goulbourne; Oludotun Adeyo; Peter Gin; Constance Voss; André Bensadoun; Loren G Fong; Stephen G Young; Anne P Beigneux
Journal:  Biochim Biophys Acta       Date:  2014-04-02

10.  Sex-associated effect of CETP and LPL polymorphisms on postprandial lipids in familial hypercholesterolaemia.

Authors:  Katherine K Anagnostopoulou; Genovefa D Kolovou; Peggy M Kostakou; Constantinos Mihas; Georgios Hatzigeorgiou; Christina Marvaki; Dimitrios Degiannis; Dimitri P Mikhailidis; Dennis V Cokkinos
Journal:  Lipids Health Dis       Date:  2009-06-26       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.